Actualité - ESMO

ESMO 2018: nearly 50 Institut Curie colleaguess in attendance

Mathilde Regnault
10/18/2018
Share
Munich is hosting the ESMO’s prestigious oncology congress from 19 to 23 October. Thanks to around 20 presentations and posters, a stand in the exhibition space and nearly 50 colleagues in attendance, Institut Curie will be well represented.
ESMO 2018 infographie

ESMO’s annual congress is a major highlight in Europe’s oncology calendar. Every year, Institut Curie colleagues attend the event to present their most recent findings. This year is set to be particularly active, with presentations and posters covering many of Institut Curie’s flagship fields, including immunotherapy, breast cancer, childhood cancer, lung cancer, epigenetics and early clinical trials, among others.

Get real-time articles and educational videos explaining the results of the main presentations on this page. And follow us live on Twitter: @Institut_Curie #ESMO18

Key highlights:

BRCA genes : new applications and new precautions

An innovative cancer treatment reveals new uses in understanding alterations in BRCA genes in some patients. Yet as Pr Dominique Stoppa-Lyonnet, head of Institut Curie’s genetics department and professor at Paris-Descartes University will explain at the ESMO congress in Munich on 19 October, these patients must be given the right information and support. More information

Clinical trial : promising results for boosting the effects of radiotherapy

The goal behind the international phase III trial promoted by Nanobiotix* was to potentiate the action of radiotherapy by using hafnium nanoparticles, with Dr. Sylvie Bonvalot serving as the principal investigator and coordinator. And the goal was accomplished with flying colors based on the initial findings presented at the ESMO congress. More information on the clinical trial

Lung cancer: profiling patients for tailored treatments

A study by Dr. Emanuela Romano at Institut Curie aims to identify the patients most likely to benefit from immunotherapy for non-small cell lung cancer. 

Find out more

Epigenetic insights into Ewing sarcoma

Ewing tumors imply genetic alterations that in turn imply epigenetic modifications. Olivier Delattre, a specialist in this type of cancer at Institut Curie, will be speaking at the ESMO congress to invite the scientific and medical community to delve deeper into this subject.

Find out more

Tumor sequencing for access to new medication

Four years ago, Institut Curie was one of the first establishments to offer patients access to a multidisciplinary molecular consultation meeting (RCP) (MCM). On 22 October, Prof. Christophe Le Tourneau will present the meeting’s working methods and benefits at the ESMO congress.

Find out more

Bone metastases: precision rays thanks to stereotaxie

Used to fight some forms of bone metastases, radiotherapy may significantly improve patients’ quality of life. Prof. Philip Poortmans, Head of the Oncology/Radiotherapy Department at Institut Curie, will share current approaches in the field with colleagues at the ESMO congress. More information

Sur place : venez nous rendre visite sur le stand 270 !